Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2013 | 02:25pm CET
   By Ben Fox Rubin 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
01:09p CELGENE CORPORATION (NASDAQ : CELG) Presents Encouraging Phase 2 tnAcity Clinica..
12/07 CELGENE : ABOUND Data Presented at the World Conference on Lung Cancer Further E..
12/07 CELGENE : tnAcity Data Presented at SABCS Evaluates the Investigational Use of A..
12/06 CELGENE : Phase III Studies Present Additional Evidence for REVLIMID® (lenalidom..
12/06 CELGENE : ABOUND Data Presented at the World Conference on Lung Cancer Further E..
12/06 CELGENE : Combined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hem..
12/05 CELGENE : Acceleron and Celgene Announce Updated Results from Phase 2 Studies of..
12/05 CELGENE : Acceleron and Celgene Announce Preliminary Results from an Investigato..
12/04 CELGENE : Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 St..
12/04 CELGENE CORPORATION : Dana-Farber Cancer Institute and University of Arkansas fo..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12:11p DRUG PRICING WILL MODERATE INDEPENDE : Stock Winners Will Be Driven By Increases..
12/07 ET TU, DONALD? DRUGS DIVE : What's Going On, And What's Next
12/07 Why Is AbbVie A Strong Buy In 2016? Part 1
12/06 Seattle's Aspirations Versus Big Pharma's Appetites
12/06 The Most And Least Loved Stocks In The S&P 500
Financials ($)
Sales 2016 11 290 M
EBIT 2016 5 861 M
Net income 2016 2 540 M
Debt 2016 5 032 M
Yield 2016 -
P/E ratio 2016 35,54
P/E ratio 2017 20,67
EV / Sales 2016 8,18x
EV / Sales 2017 6,95x
Capitalization 87 334 M
More Financials
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 139 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-13.02%105 034
GILEAD SCIENCES, INC.-28.08%95 884
ACTELION LTD45.20%22 191
More Results